← Evidence map

TrialThe Lancet. Oncology2026

MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.

Fleur M Louis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2026

this papercites it

MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study. | OpenQuestion